On August 29, 2022 Shanghai UniCar Therapy reported that closed a Series C financing to advance clinical trials of its ssCART-19 injection in patients with leukemia (Press release, Unicar-Therapy Bio-medicine , AUG 29, 2022, View Source [SID1234618796]). Guan Bang Fund and Junci Investment were the two named investors in the C round. UniCar’s ssCART-19 injection, the company’s lead CAR-T 2.0, expresses single-chain antibodies targeting CD19 and IL-6 silencing elements (shRNA). The company expects IL-6 silencing will decrease cytokine release syndrome in patients. UniCar focuses on refining CAR-T products to increase their efficacy. The company said the C round raised "tens of millions of RMB."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!